论文部分内容阅读
目的研究SLCO1B1基因多态性对阿托伐他汀的降脂活性的影响。方法纳入初次接受阿托伐他汀治疗,用药时间超过15天且临床记录完整的,无合并应用其他影响血脂水平药物的患者。收集患者临床数据,测定患者治疗前后血脂水平,检测患者SLCO1B1-521T>C(rs4149056)和一388A>G(rs2306283)基因多态性。结果研究纳入患者56例,各位点基因型分布符合Hardy-Weinberg平衡(P>0.05)。SLCO1B1-388GG基因型亚组患者的TC、LDL-C和TG降低幅度均显著高于(AA+AG)基因型亚组患者。结论中国患者中SLCO1B1基因多态性,特别是-388A>G与阿托伐他汀药物的降脂效应相关。
Objective To investigate the effect of SLCO1B1 gene polymorphism on the lipid-lowering activity of atorvastatin. Methods Patients were enrolled in initial atorvastatin treatment for more than 15 days with complete clinical records and no other drugs that affected blood lipid levels. The clinical data of patients were collected, the blood lipid levels of patients before and after treatment were measured, and the gene polymorphisms of SLCO1B1-521T> C (rs4149056) and 388A> G (rs2306283) were detected. Results Fifty-six patients were included in the study. The distribution of genotypes in each locus was in accordance with Hardy-Weinberg equilibrium (P> 0.05). The reduction of TC, LDL-C and TG in patients with SLCO1B1-388GG genotype were significantly higher than those in patients with (AA + AG) genotype. Conclusions SLCO1B1 gene polymorphisms in Chinese patients, especially -388A> G, are associated with lipid-lowering effects of atorvastatin medications.